Clinical Trials to authors: Please pre-register your studies!
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Works matching IS 17407745 AND DT 2021 AND VI 18 AND IP 6
Results: 16
1
2
Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 673, doi. 10.1177/17407745211052486
- By:
- Publication type:
- Article
3
Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 690, doi. 10.1177/17407745211052474
- By:
- Publication type:
- Article
4
Commentary on Price and Scott: Complex innovative trial design.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 711, doi. 10.1177/17407745211050601
- By:
- Publication type:
- Article
5
The U.S. Food and Drug Administration's Complex Innovative Trial Design Pilot Meeting Program: Progress to date.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 706, doi. 10.1177/17407745211050580
- By:
- Publication type:
- Article
6
Incentives and payments in pragmatic clinical trials: Scientific, ethical, and policy considerations.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 699, doi. 10.1177/17407745211048178
- By:
- Publication type:
- Article
7
Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 681, doi. 10.1177/17407745211045734
- By:
- Publication type:
- Article
8
Why restricted mean survival time methods are especially useful for non-inferiority trials.
- Published in:
- 2021
- By:
- Publication type:
- Letter
9
Reply to Quartagno et al.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 746, doi. 10.1177/17407745211045123
- By:
- Publication type:
- Article
10
Application of tetrad testing to the evaluation of blinding strategies for ancillary supplies used in controlled clinical trials.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 667, doi. 10.1177/17407745211044119
- By:
- Publication type:
- Article
11
Characteristics of available studies and dissemination of research using major clinical data sharing platforms.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 657, doi. 10.1177/17407745211038524
- By:
- Publication type:
- Article
12
Clinical trial site identification practices and the use of electronic health records in feasibility evaluations: An interview study in the Nordic countries.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 724, doi. 10.1177/17407745211038512
- By:
- Publication type:
- Article
13
On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 714, doi. 10.1177/17407745211034497
- By:
- Publication type:
- Article
14
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 647, doi. 10.1177/17407745211032909
- By:
- Publication type:
- Article
15
Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.
- Published in:
- Clinical Trials, 2021, v. 18, n. 6, p. 732, doi. 10.1177/17407745211030683
- By:
- Publication type:
- Article
16
What do we do with our under-enrolled single-center COVID-19 clinical trials?
- Published in:
- 2021
- By:
- Publication type:
- Letter